Cancer Biologics Market to grow with a CAGR of 7.17% through 2030

Increasing healthcare infrastructure and a supportive regulatory environment are the major drivers for the Global Cancer Biologics Market.

According to TechSci Research report, “Cancer Biologics Market - Global Industry Size, Share, Trends, Competition, Opportunity and Forecast, 2020-2030F”, Global Cancer Biologics Market was valued at USD 94.10 billion in 2024 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 7.17% through 2030. 

Immune checkpoint inhibitors, such as anti-PD-1 and anti-PD-L1 antibodies, have revolutionized cancer treatment. They block inhibitory signals that prevent the immune system from recognizing and attacking cancer cells. Immunotherapies have demonstrated remarkable success in various cancer types, including melanoma, lung cancer, and more. Chimeric Antigen Receptor T-cell (CAR-T) therapy is a groundbreaking approach where a patient's own T cells are genetically modified to express a receptor that targets cancer cells. CAR-T therapies have shown remarkable results in certain blood cancers, such as leukemia and lymphoma. Bispecific antibodies can target two different antigens simultaneously, often on both cancer cells and immune cells. These innovative antibodies enhance the immune system's ability to recognize and attack cancer cells, leading to improved treatment outcomes. Advancements in genomics and biomarker research have enabled the development of biologics tailored to specific genetic mutations and protein markers present in cancer. This personalized approach improves treatment efficacy and reduces side effects. The development of biosimilars, which are highly similar but more affordable versions of established biologics, has increased access to cancer treatments, potentially lowering healthcare costs. Monoclonal antibodies continue to be at the forefront of cancer biologics development. New monoclonal antibodies are constantly being researched and developed to target specific cancer markers and pathways.

Cancer vaccines, such as the human papillomavirus (HPV) vaccine and therapeutic cancer vaccines, have been developed to prevent certain types of cancer and boost the body's immune response against existing cancer cells. Targeted biologics have been designed to interfere with specific pathways that drive cancer growth. These therapies aim to disrupt the molecular signals that allow cancer cells to proliferate while sparing healthy cells. Researchers are investigating the synergistic effects of combining different biologics, such as combining immunotherapies with targeted therapies or chemotherapy. These combinations aim to enhance the overall therapeutic impact and reduce the likelihood of resistance. Advancements in gene editing technologies, such as CRISPR-Cas9, offer the potential to modify cancer cells or enhance the body's immune response to cancer. The use of nanoparticles for drug delivery and targeting specific cancer cells has gained attention. Nanotechnology can improve drug delivery efficiency and reduce side effects. Biologics production has become more efficient and scalable, ensuring consistent product quality and supply. Advanced manufacturing techniques have reduced production costs. The development of companion diagnostic tests helps identify the most suitable patients for specific biologic therapies, ensuring a more targeted and effective approach to treatment. This factor will help in the development of the Global Cancer Biologics Market.

Browse over XX market data Figures and spread through XX Pages and an in-depth TOC on " Global Cancer Biologics Market”

Global Cancer Biologics Market is segmented based on Products, Application, End User, and by region.  

Based on product,  In 2024, the Global Cancer Biologics Market largest share was held by Immune Checkpoint Inhibitors segment and is predicted to continue expanding over the coming years. Immune checkpoint inhibitors, such as PD-1 and PD-L1 inhibitors, have shown remarkable efficacy in treating a wide range of cancer types, including melanoma, lung cancer, kidney cancer, bladder cancer, and more. Their ability to harness the immune system's natural response to fight cancer has made them a valuable option in the oncology field. Several immune checkpoint inhibitors have demonstrated significant clinical success, often leading to improved patient survival rates and durable responses. This success has fuelled their widespread adoption. Regulatory bodies, such as the U.S. Food and Drug Administration (FDA), have granted approvals for various immune checkpoint inhibitors for multiple cancer indications. These approvals provide healthcare providers with well-established treatment options. Immune checkpoint inhibitors can be used as monotherapy or in combination with other biologics, chemotherapy, or targeted therapies. This versatility allows oncologists to tailor treatment plans to individual patients and their specific cancer types. Immune checkpoint inhibitors are often used in conjunction with biomarker testing, allowing for more precise patient selection. Patients with specific biomarker profiles are more likely to benefit from these therapies, increasing their effectiveness. A robust pipeline of immune checkpoint inhibitors in various stages of clinical trials continually expands the treatment landscape. Clinical trial results have often led to new approvals and indications.

Some of the major companies operating in the Global Cancer Biologics Market include:

• Roche Holding AG
• Novartis AG
• Merck & Co., Inc.
• Bristol-Myers Squibb Company
• Amgen Inc.
• Johnson & Johnson
• Pfizer Inc.
• AstraZeneca plc
• Eli Lilly and Company
• AbbVie Inc.

Download Free Sample Report

Customers can also request for 10% free customization on this report.

“Certain areas, particularly in North America, are projected to exert significant demand for Cancer Biologics. The growth in the competitive landscape and the presence of well-established companies in the market, committed to enhance the overall wellbeing of people each year, are expected to contribute to a remarkable growth of the Global Cancer Biologics Market in the forecast period," said Mr. Karan Chechi, Research Director, TechSci Research, a research-based Global management consulting firm.

"Cancer Biologics Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product (Monoclonal Antibodies, Cytokine-Based Immunotherapy, Cancer Vaccines, CAR-T Cell Therapy, Immune Checkpoint Inhibitors), By Application (Non-small Cell Lung Cancer, Prostate Cancer, Breast Cancer, Acute Myeloid Leukemia, Lymphoma, Others), by End User (Hospitals & Clinics, Ambulatory Care Centers, Others), By Region & Competition 2020-2030F", has evaluated the future growth potential of Global Cancer Biologics Market and provides statistics & information on market size, structure, and future market growth. The report intends to provide innovative market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in Global Cancer Biologics Market.

Contact

Techsci Research LLC

420 Lexington Avenue, Suite 300,

New York, United States- 10170

Tel: +13322586602

Email: sales@techsciresearch.com               

Website: www.techsciresearch.com